Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)
Run by European Partnership for Personalised Medicine · Needs partners
What this call funds
This call funds transnational research projects developing and validating new cell and gene therapies for personalised medicine. Projects must use at least one of several approaches such as somatic cell therapeutics, gene therapeutics, combined cell and gene therapeutics, or novel biological products. The total budget available is around 38 million euros, co-funded by the EU and national funding bodies.
biotechnology · pharmaceuticals · digital health · genomics · diagnostics
Who wins this
A multinational consortium of academic, clinical and private research teams working on innovative cell or gene therapy approaches for personalised medicine.
Could you win this call?
Only the website is required.
The call in detail
- Submission
- Single-stage submission (full proposal at once)
- Type of action
- Cascade funding
- Partners
- Required. The call asks for a consortium: from 2 countries.
- Eligible applicants
- research organisation, public body, SME, large enterprise
- Also required
- Applicants must follow national or regional funding regulations in addition to the joint call rules, and within a German consortium funding may only be requested from one national funding body.
- Eligible countries (45)
- Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Norway, Iceland, Switzerland, United Kingdom, Israel, Türkiye, Ukraine, Serbia, North Macedonia, Montenegro, Albania, Bosnia and Herzegovina, Kosovo, Georgia, Armenia, Moldova, Tunisia, New Zealand
Who has won calls like this
Organisations that most often win this call family · 32 past winners